Conjuntivitis con Dupilumab

Dupilumab May Make Patients Vulnerable To Conjunctival Inflammation, Researchers Say.

MedPage Today (12/13, Susman) reports six patients taking dupilumab for atopic dermatitis developed conjunctival inflammation, according to a presentation given at the Inflammatory Skin Disease Summit. The researchers described how dupilumab can "help control atopic dermatitis by diminishing interleukin (IL)-13, but that same mechanism of action may make a patient's eyes vulnerable to conjunctival inflammation." Daphne Bakker, MD, PhD candidate, presented the data and said, "Our findings indicate that dupilumab‐related conjunctivitis is marked by goblet cell scarcity in the conjunctival epithelium accompanied by a T‐cell and eosinophilic infiltrate. More insight in the functional T-cell profile and activation status of eosinophils is necessary to further clarify the underlying pathomechanism of conjunctivitis during dupilumab treatment in atopic dermatitis patients."